Last reviewed · How we verify

Serostim® — Competitive Intelligence Brief

Serostim® (Serostim®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone (recombinant human somatropin). Area: Infectious Disease / Endocrinology.

marketed Growth hormone (recombinant human somatropin) Growth hormone receptor (GHR) Infectious Disease / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Serostim® (Serostim®) — EMD Serono. Serostim is a recombinant human growth hormone that stimulates anabolic processes and increases lean body mass in patients with HIV-associated wasting.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Serostim® TARGET Serostim® EMD Serono marketed Growth hormone (recombinant human somatropin) Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone (recombinant human somatropin) class)

  1. EMD Serono · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Serostim® — Competitive Intelligence Brief. https://druglandscape.com/ci/serostim. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: